Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma
Executive Summary
This briefing document synthesizes the findings of a retrospective study published in the Journal of Cancer (2021) regarding the optimal timing of Transarterial Chemoembolization (TACE) for patients with large Hepatocellular Carcinoma (HCC) undergoing Liver Resection (LR). Based on an analysis of 320 patients with tumors larger than 5 cm, the study concludes that preoperative TACE provides significantly better prognosis than postoperative TACE in terms of both Overall Survival (OS) and Recurrence-Free Survival (RFS).
Key takeaways include:
Survival Superiority: After Propensity Score Matching (PSM), patients receiving preoperative TACE showed a 5-year OS rate of 53.4% compared to 32.3% for the postoperative group.
Recurrence Control: Preoperative TACE significantly reduced recurrence rates, with a 5-year RFS of 31.4% versus 14.7% for postoperative TACE.
Treatment Efficiency: A single TACE treatment appears sufficient; additional TACE sessions did not yield significant improvements in survival or recurrence rates.
Prognostic Factors: Postoperative TACE timing, macrovascular invasion, microvascular invasion (MVI), and cirrhosis were identified as independent risk factors for poorer outcomes.
Study Overview and Methodology
The study sought to resolve the ongoing controversy regarding whether TACE is more effective as a neoadjuvant (preoperative) or adjuvant (postoperative) therapy when combined with curative liver resection for large HCC.
Patient Cohort and Selection
Total Patients: 320 consecutive patients (January 2009 to December 2014) at Sun Yat-sen University Cancer Center.
Demographics: Median age of 48; 89.1% were male.
Inclusion Criteria: Tumors > 5 cm, Child-Pugh grade A or B, no extrahepatic metastases, and curative (R0) resection.
Groups:
Preoperative TACE (TACE + LR): 199 patients.
Postoperative TACE (LR + TACE): 121 patients.
Statistical Balancing
To account for baseline differences—such as the postoperative group having higher rates of microvascular invasion and high alpha-fetoprotein (AFP) levels—researchers employed Propensity Score Matching (PSM). This resulted in two comparable groups of 89 patients each, ensuring the findings were not skewed by pre-existing clinical biases.
Comparative Survival Outcomes
The study found that the timing of TACE is a critical determinant of long-term patient survival.
Overall Survival (OS)
Preoperative TACE consistently outperformed postoperative TACE across all measured intervals.
Recurrence-Free Survival (RFS)
Preoperative TACE demonstrated a superior ability to prevent or delay tumor recurrence.
Analysis of Independent Risk Factors
Multivariate Cox regression analysis identified specific clinicopathological characteristics that significantly increased the risk of death or recurrence after matching.
Risk Factors for Poorer Overall Survival
Macrovascular Invasion: Hazard Ratio (HR) of 3.98 (the strongest predictor of mortality).
Postoperative TACE Timing: HR of 1.92 (indicating nearly double the risk of death compared to preoperative TACE).
Cirrhosis: HR of 2.48.
Microvascular Invasion (MVI): HR of 1.64.
Risk Factors for Tumor Recurrence
Macrovascular Invasion: HR of 3.34.
Microvascular Invasion (MVI): HR of 2.24.
Tumor Number (Multiple vs. Single): HR of 1.99.
Tumor Diameter: HR of 1.94.
Cirrhosis: HR of 1.91.
Postoperative TACE Timing: HR of 1.64.
Clinical Implications and Mechanisms
The study provides several insights into why preoperative TACE is more effective for large HCC management.
The Superiority of Preoperative TACE
Reduction of Micrometastases: Large HCC tumors are frequently associated with occult micrometastases that imaging cannot detect. Preoperative TACE may destroy these early-stage foci by interrupting tumor blood supply before surgery.
Reduction of Microvascular Invasion (MVI): Evidence suggests preoperative TACE induces massive tumor necrosis, which significantly reduces the presence of MVI, a known driver of poor prognosis.
Surgical Feasibility: While some suggest preoperative TACE makes surgery more difficult due to inflammation, this study found no statistically significant difference in intraoperative blood loss or transfusion volumes after PSM.
Limitations of Postoperative TACE
The document suggests that TACE administered after liver resection may be less effective for two reasons:
Liver Function Deterioration: The trauma of removing a large volume of liver tissue followed by TACE may accelerate the decline of liver function.
Immune Suppression: Postoperative TACE may contribute to the suppression of the host's immune response against tumor progression and negatively impact hepatocyte regeneration.
Treatment Frequency
The analysis revealed that multiple TACE treatments do not provide additional benefits. Patients who underwent a single TACE session had OS and RFS rates similar to those who underwent two or more treatments. A single session, including hepatic angiography, is sufficient to identify satellite nodules and disrupt the local vascular supply.
Conclusions
For patients with large HCC (> 5 cm) undergoing curative resection, preoperative TACE is the superior adjuvant strategy. It offers a clinically sizable benefit in survival and disease control over postoperative TACE. Furthermore, the management of these patients should focus on a single, well-timed preoperative TACE treatment to maximize prognostic benefits while avoiding unnecessary procedural repetition.
